Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 4,245	$ 0	$ 9,989	$ 120
Operating expenses
Selling, general and administrative	9,915	7,401	29,069	8,793
Research and development	8,773	5,754	23,292	12,443
Cost of goods sold	593	0	1,113	0
Impairment of acquired contract intangible asset	0	74,156	3,724	74,156
Total operating expenses	19,281	87,311	57,198	95,392
Loss from operations	(15,036)	(87,311)	(47,209)	(95,272)
Other income (expense)
Change in fair value of convertible promissory notes	0	380	0	1,585
Gain upon extinguishment of debt	0	0	0	196
Interest income	620	0	791	1
Interest expense	(58)	(157)	(173)	(608)
Total other income, net	562	223	618	1,174
Loss before income tax expense	(14,474)	(87,088)	(46,591)	(94,098)
Income tax expense	0	0	(9)	(2)
Net loss	(14,474)	(87,088)	(46,600)	(94,100)
Other comprehensive loss:
Change in unrealized loss on short-term investments	(99)	0	(99)	0
Comprehensive loss	$ (14,573)	$ (87,088)	$ (46,699)	$ (94,100)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.68)	$ (9.17)	$ (2.21)	$ (19.37)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.68)	$ (9.17)	$ (2.21)	$ (19.37)
Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)	21,269,163	9,510,379	21,052,786	4,890,556
Weighted-average common shares outstanding, diluted (in shares)	21,269,163	9,510,379	21,052,786	4,890,556
Product sales, net
Total revenue	$ 4,245	$ 0	$ 9,989	$ 0
Grant revenue
Total revenue	$ 0	$ 0	$ 0	$ 120